Abivax S.A.
- ABVX
- NASDAQ
- Biotechnology
- Anti-Inflammatory Drugs
- Infectious Disease Therapeutics
- Clinical-Stage Biotech
$87.84
Today −0.33%Quote Oct 19, 2026, 06:39 PM UTC
−17.63%over the last month
Max drawdown −19.4%From 1-month high −17.6%3 months −33.0%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Abivax
Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. A cornerstone of their product pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's Disease, and COVID-19.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
80
Founded
2013
Market value
$6.90B
Quote Oct 19
Floor
$83.62
4.8% below price
Resistance
$88.64
0.9% above price
Price vs analyst targets
13 analysts
Lowest target
$118.00Highest target
$180.00
$118.00Highest target
$180.00
- Price $87.84
- Average target $156.00
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 78% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about ABVXPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free